Online inquiry

IVTScrip™ mRNA-Anti-FASLG, APG-101(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ3090MR)

This product GTTS-WQ3090MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets FASLG gene. The antibody can be applied in Glioblastoma multiforme (GBM) research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_000639.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 356
UniProt ID Q53ZZ1
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-FASLG, APG-101(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) (GTTS-WQ3090MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ13627MR IVTScrip™ mRNA-Anti-TNFSF4, R4930(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA R4930
GTTS-WQ13380MR IVTScrip™ mRNA-Anti-PRLR, PR-1594804(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA PR-1594804
GTTS-WQ14162MR IVTScrip™ mRNA-Anti-IL6R, aIL6R88(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA aIL6R88
GTTS-WQ8055MR IVTScrip™ mRNA-Anti-CD33, h2H12ec(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA h2H12ec
GTTS-WQ92MR IVTScrip™ mRNA-Anti-KDR, 1121B(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA 1121B
GTTS-WQ9017MR IVTScrip™ mRNA-Anti-MST1R, IMC RON-8(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA IMC RON-8
GTTS-WQ8159MR IVTScrip™ mRNA-Anti-TNFRSF1A, HL036337(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA HL036337
GTTS-WQ14141MR IVTScrip™ mRNA-Anti-PCSK9, aPCSK927(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA aPCSK927
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW